|
|
Article: Inhale Reports Diabetes Product Effective In Phase III Clinical Trial.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Inhale Therapeutic Systems Inc. reported Monday on Phase III studies conducted by Pfizer Inc., of New York. The data show that patients with Type II diabetes who had failed to meet recommended blood glucose levels with combination oral therapy achieved better glycemic control with Exubera inhaled insulin than patients who received only oral agents. The study also showed that Exubera inhaled insulin provided glycemic control equal to insulin injections in patients with Type I diabetes.
The data were presented at the 62nd annual scientific sessions of the American Diabetes Association in San Francisco that began Saturday and continues through today.
The ...